Literature DB >> 10534309

Identification of human cytochrome P-450 isoforms involved in metabolism of R(+)- and S(-)-gallopamil: utility of in vitro disappearance rate.

A Suzuki1, I Iida, F Tanaka, M Akimoto, K Fukushima, M Tani, T Ishizaki, K Chiba.   

Abstract

Isoforms of cytochrome P-450 (CYP) involved in the metabolism of gallopamil enantiomers were identified by measuring the disappearance rate of parent drug from an incubation mixture with human liver microsomes and recombinant human CYPs. Mean (+/- S.D.) intrinsic clearances (CL(int)) of R(+)- and S(-)-gallopamil in human liver microsomes were 0.320 +/- 0.165 and 0.205 +/- 0.107 ml/min/mg protein, respectively. These values were highly correlated with the 6beta-hydroxylation activity of testosterone, a marker substrate of CYP3A4 (r = 0.977 and 0.900 for R(+)- and S(-)-gallopamil, respectively, p <.001). Ketoconazole and troleandomycin, selective inhibitors of CYP3A4, and polyclonal antibodies raised against CYP3A4/5 markedly reduced the CL(int) of gallopamil enantiomers in human liver microsomes. Among the 10 recombinant human CYP isoforms, CYP3A4 exhibited the highest CL(int) of gallopamil enantiomers, and CYP2C8 and CYP2D6 also exhibited appreciable activity. When the contribution of CYP3A4 to the total metabolic clearance of gallopamil enantiomers in human liver microsomes was estimated by relative activity factor, the mean (+/- S.D.) contributions were 92 +/- 18 and 68 +/- 19% for R(+)- and S(-)-gallopamil, respectively. These values were comparable to the rates of immunoinhibition by antibodies raised against CYP3A4/5 observed in human liver microsomes. The present study suggests that CYP3A4 is a major isoform involved in the overall metabolic clearance of gallopamil enantiomers in the human liver, and that the present approach based on disappearance rate may be applicable to identify major isoforms of CYP involved in the metabolism of a drug in human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534309

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

1.  A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology.

Authors:  Matthew G Soars; Harry V Gelboin; Kristopher W Krausz; Robert J Riley
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

2.  Involvement of human liver cytochrome P4502B6 in the metabolism of propofol.

Authors:  Y Oda; N Hamaoka; T Hiroi; S Imaoka; I Hase; K Tanaka; Y Funae; T Ishizaki; A Asada
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

3.  The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.

Authors:  Carmen Martínez; Elena García-Martín; Gerardo Blanco; Francisco J G Gamito; José M Ladero; José A G Agúndez
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

4.  The in vitro metabolism of desglymidodrine, an active metabolite of prodrug midodrine by human liver microsomes.

Authors:  Masayuki Akimoto; Izumi Iida; Hiroki Itoga; Atsunori Miyata; Shizuko Kawahara; Yoshiro Kohno
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jul-Sep       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.